Skip to main content

Table 2 Cell viabilities in the presence of DOPAC–Fe3O4@TiO2 nanoconjugates following irradiation

From: Development of Fe3O4 core–TiO2 shell nanocomposites and nanoconjugates as a foundation for neuroblastoma radiosensitization

DOPAC–Fe3O4@TiO2 0 nM 100 nM 250 nM
SK-N-AS 0 Gy 100 ± 5.06 100 ± 4.50 100 ± 10.11
2 Gy 91.84 ± 5.50 57.60 ± 7.28*** 53.50 ± 6.60***
5 Gy 59.38 ± 4.79 26.40 ± 5.56*** 17.94 ± 4.54***
10 Gy 38.11 ± 2.35 14.53 ± 3.50*** 7.58 ± 5.67***
SK-N-DZ 0 Gy 100 ± 10.12 100 ± 9.28 100 ± 17.87
2 Gy 51.97 ± 4.34 40.35 ± 10.15* 36.83 ± 17.71
5 Gy 40.06 ± 3.35 27.55 ± 3.86*** 20.78 ± 12.76**
10 Gy 17.52 ± 3.23 8.25 ± 3.84** 5.20 ± 10.43*
  1. Table of cell viabilities (expressed as % of non-irradiated treatment control for a given concentration of nanoconjugates, after adjustment for baseline cytotoxicity) for SK-N-AS and SK-N-DZ cells treated with varying concentrations of DOPAC-nanocomposites combined with varying doses of ionizing radiation, from Fig. 5. Entries contain mean ± SD. *: < 0.05 significance level, **: < 0.01 significance level, *** < 0.001 significance level